D
Douglas J. Biedenbach
Researcher at University of Iowa
Publications - 140
Citations - 5975
Douglas J. Biedenbach is an academic researcher from University of Iowa. The author has contributed to research in topics: Etest & Broth microdilution. The author has an hindex of 42, co-authored 140 publications receiving 5791 citations.
Papers
More filters
Journal ArticleDOI
Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002)
TL;DR: Patient age analysis showed the most common BSI pathogen among neonates was coagulase-negative staphylococci and among elderly patients, E. coli; resistance among BSI pathogens was much more prevalent in nosocomial infections and in patients in intensive care units (ICUs); age differences were also noted.
Journal ArticleDOI
Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
TL;DR: The morbidity and cost for cure associated with skin and soft tissue infections (SSTIs) have recently become more complicated because of the increasing prevalence of multidrug-resistant pathogens associated with this healthcare problem.
Journal ArticleDOI
Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program
Lalitagauri M. Deshpande,Thomas R. Fritsche,Gary J. Moet,Douglas J. Biedenbach,Ronald N. Jones +4 more
TL;DR: Clonal spread appears to be a dominant factor of MDR VRE dissemination on both continents, and further monitoring is critical to assist in the control of these resistant pathogens.
Journal ArticleDOI
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.
Sujata M. Bhavnani,Julie A. Drake,Alan Forrest,June A. Deinhart,Ronald N. Jones,Douglas J. Biedenbach,Charles H. Ballow +6 more
TL;DR: Results from both LR and CART indicated that patients with persisting enterococcal bacteremia, intubation at baseline, higher APACHE II scores, and VRE bactseremia were at greater risk for poor outcome.
Journal ArticleDOI
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
TL;DR: Overall, quinupristin-dalfopristin was consistently active against major Gram-positive pathogens in North America, regardless of resistance patterns to other drug classes and geographic location of their isolation.